| sess_SDA-2026-04-08- | The debate noted clinical failures of TNF-α and IL-6 inhibitors in AD despite th | 0.79 | 7 | 4 | completed | 2026-04-10 | SDA-2026-04-08-gap-debate-20260406-062045-ce866189 |
| sess_SDA-2026-04-08- | The debate identified fundamental druggability challenges for these targets due | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd |
| sess_SDA-2026-04-08- | The highest-ranked hypothesis assumes senescence reversibility through metabolic | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062101-7751c220 |
| sess_SDA-2026-04-08- | The authors identify SPI1 as a potential transcription factor regulating the hub | 0.93 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062122-bfac06c8 |
| sess_SDA-2026-04-08- | The study reports that complement-mediated synaptic elimination produces both co | 0.83 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062128-34a47c4e |
| sess_SDA-2026-04-08- | While the abstract establishes that intercellular transmission occurs for variou | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062207-5a703c17 |
| sess_SDA-2026-04-08- | The study identifies ADCY8 as associated with migratory distance differences and | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062218-580b17ef |
| sess_SDA-2026-04-08- | While APOE4 disrupts microglial metabolism broadly, the debate didn't identify w | 0.92 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-debate-20260406-062033-fecb8755 |
| sess_SDA-2026-04-08- | The abstract notes that clinical presentations overlap across different myelopat | 0.86 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062111-db808ee9 |
| sess_SDA-2026-04-08- | The paper describes memory-based migration routes maintained across generations | 0.95 | 7 | 4 | completed | 2026-04-09 | SDA-2026-04-08-gap-pubmed-20260406-062218-5c7f15f4 |
| sess_astrocyte-subty | Astrocyte Reactivity Subtypes in Neurodegeneration | 0.95 | 7 | 4 | completed | 2026-04-09 | astrocyte-subtypes |
| sess_sda-2026-04-01- | Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engi | 0.91 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-008 |
| sess_sda-2026-04-01- | Microglia activate astrocytes via IL-1alpha/TNF/C1q, and reactive astrocytes fee | 0.90 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-009 |
| sess_sda-2026-04-01- | APOE4 differs from APOE3 by C112R causing domain interaction that alters lipid b | 0.89 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-010 |
| sess_sda-2026-04-01- | Multiple NDDs converge on autophagy-lysosome dysfunction. Are there universal th | 0.90 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-011 |
| sess_sda-2026-04-01- | Can speech, gait, retinal imaging, sleep, and smartphone data detect neurodegene | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-012 |
| sess_sda-2026-04-01- | Senolytics targeting p16/p21+ senescent astrocytes and microglia may reduce SASP | 0.89 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-013 |
| sess_sda-2026-04-01- | SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re | 0.83 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-014 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.81 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-20260401231108 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.53 | 1 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-9137255b |
| sess_sda-2026-04-01- | Can gut-brain axis modulation prevent or slow Alzheimer's disease pathology? | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-003 |
| sess_sda-2026-04-01- | How to break the GBA-alpha-synuclein bidirectional loop for Parkinson's Disease | 0.90 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-002 |
| sess_sda-2026-04-01- | What are the most promising therapeutic strategies for targeting TREM2 in Alzhei | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-001 |
| sess_sda-2026-04-01- | Analysis question not specified | 0.87 | 3 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-auto-fd6b1635d9 |
| sess_sda-2026-04-01- | Sleep disruption as cause and consequence of neurodegeneration | 0.91 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-18cf98ca |
| sess_sda-2026-04-01- | RNA binding protein dysregulation across ALS FTD and AD | 0.88 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-68d9c9c1 |
| sess_sda-2026-04-01- | Synaptic pruning by microglia in early AD | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-691b42f1 |
| sess_sda-2026-04-01- | Mitochondrial transfer between astrocytes and neurons | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-89432b95 |
| sess_sda-2026-04-01- | Epigenetic clocks and biological aging in neurodegeneration | 0.93 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-bc5f270e |
| sess_sda-2026-04-01- | Perivascular spaces and glymphatic clearance failure in AD | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-v2-ee5a5023 |
| sess_sda-2026-04-01- | What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's | 0.95 | 7 | 4 | completed | 2026-04-07 | sda-2026-04-01-gap-20260401-225149 |
| sess_SDA-2026-04-06- | TREM2 Therapeutic Strategy Post-INVOKE-2 | 0.93 | 7 | 4 | completed | 2026-04-06 | SDA-2026-04-06-gap-001 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early AD | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| sess_SDA-2026-04-04- | Neuroinflammation and microglial priming in early Alzheimer's Disease | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 |
| sess_SDA-2026-04-04- | Tau propagation mechanisms and therapeutic interception points | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| sess_SDA-2026-04-04- | Senescent cell clearance as neurodegeneration therapy | 0.95 | 7 | 3 | completed | 2026-04-04 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| sess_analysis_sea_ad | What are the cell-type specific vulnerability mechanisms in Alzheimer's disease | 0.68 | 0 | 4 | completed | 2026-04-04 | analysis_sea_ad_001 |
| sess_SDA-2026-04-04- | SEA-AD Single-Cell Analysis: Cell-Type Vulnerability in Alzheimer's Disease | 0.88 | 5 | 4 | completed | 2026-04-04 | SDA-2026-04-04-analysis_sea_ad_001 |
| sess_SDA-2026-04-04- | Which metabolic biomarkers can distinguish therapeutic response from disease pro | 0.92 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| sess_SDA-2026-04-04- | How do neurodegeneration gene expression patterns in SEA-AD differ from other po | 0.94 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222549-20260402 |
| sess_SDA-2026-04-04- | How do astrocyte-neuron metabolic interactions change during disease progression | 0.93 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd |
| sess_SDA-2026-04-03- | The debate mentioned gene expression profiling but did not specify which neural | 0.93 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222543-20260402 |
| sess_SDA-2026-04-03- | While ketone metabolism was discussed as therapeutic, the debate revealed no cle | 0.80 | 8 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| sess_SDA-2026-04-03- | The debate highlighted TFEB's role in mitochondrial-lysosomal coupling but could | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-debate-20260403-222617-8eb5bdbc |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 6 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v2-20260402 |
| sess_SDA-2026-04-03- | What gene expression changes in the aging mouse brain predict neurodegenerative | 0.95 | 6 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-20260402 |
| sess_SDA-2026-04-03- | Evaluate the potential of CRISPR/Cas9 and related gene editing technologies for | 0.95 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-crispr-neurodegeneration-20260402 |
| sess_SDA-2026-04-03- | Comprehensive analysis of immune cell subtypes in neurodegeneration: microglia s | 0.85 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402 |
| sess_SDA-2026-04-03- | What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc | 0.92 | 7 | 4 | completed | 2026-04-04 | SDA-2026-04-03-gap-seaad-20260402025452 |